Comments on:  Nasus Pharma Announces Ground-Breaking Five Years Stability of its FMXIN002 Nasal Epinephrine Powder for Severe Allergy and Anaphylaxis   https://www.nasuspharma.com/nasus-pharma-announces-positive-clinical-results-of-recent-phase-2-study-with-fmxin002-intranasal-epinephrine-copy/?utm_source=rss&utm_medium=rss&utm_campaign=nasus-pharma-announces-positive-clinical-results-of-recent-phase-2-study-with-fmxin002-intranasal-epinephrine-copy New frontier in Intranasal drug delivery Mon, 04 Aug 2025 18:56:29 +0000 hourly 1 https://wordpress.org/?v=6.8.3